FACTORS RELATED TO PATIENT ADHERENCE TO ANTIDIABETIC DRUG THERAPY
.
M a n y f a c t o r s c a n a f f e c t t r e a t m e n t adherence and there is no consensus on which has the greatest impact. First, it should be considered whether patients have access to drugs. Ruling out the possibility of no access, patient adherence to drug therapy can be divided into four groups of factors: patient-related; related to patient-provider relationship, therapeutic regimen, and the disease itself (1, 3) .
A complex variety of determinants clearly plays a role in patient adherence to the therapeutic regimen and contributes to non-adherence of those with chronic conditions like diabetes.
There is a lack of studies investigating adherence to antidiabetic drug therapy, and those available have different designs and inconsistent results. Further investigation is needed as most studies have focused on patient adherence to antihypertensive and lipid-reducing drugs instead of to oral antidiabetic agents and insulin (4, (6) (7) .
Researchers and health providers have recently been devoting a great deal of effort to better understand non-adherence to drug therapy.
It is though a challenge as people's behaviors involve complex mechanisms. There is a need to further explore this issue in order to identify behaviors that facilitate and/or prevent adherence to drug therapy.
OBJECTIVE
To assess patient adherence to antidiabetic drug therapy and to describe its association to factors related to the patient, patient-provider relationship, therapeutic regimen, and the disease itself. o n d i a b e t e s a n d i t s m a n a g e m e n t ) a n d t h e Treatment Adherence Measure (TAM). The TAM i n s t r u m e n t c o n s i s t s o f s e v e n i t e m s a n d w a s developed and validated in Portugal with good internal consistency (p<0.001). It also showed good concurrent validity with high correlations in any answer and 0.77 sensitivity and 0.73 specificity, proving to be a good instrument for capturing a v a r i e t y o f b e h a v i o r s i n v o l v e d i n t r e a t m e n t adherence (8) .
MATERIALS AND METHODS
A literature search did not find any studies on the applicability of TAM instrument in Brazilian subjects. But given the closeness between European 
RESULTS
Of 46 (100%) subjects studied, 78.3% were adherent and 21.7% were non-adherent to drug therapy. Table 1 shows the prevalence of patient adherence to drug therapy according to factors related to the patient, patient-provider r e l a t i o n s h i p , t h e r a p e u t i c r e g i m e n , a n d t h e disease itself. Although different prevalences of adherence were found for each factor studied, these differences
were not statistically significant (p>0.05) in Fisher's exact test, as shown in Table 1 .
DISCUSSION
The prevalence of patient adherence to drug therapy for diabetes management found in the study was 78.3%. It is similar to that described in diabetes patients receiving drug therapy, 79.7% (9) . Another study showed 95.7% prevalence of adherence to antihyperglycemic agents in type 2 diabetic patients (4) .
As for patient-related factors associated to adherence to drug therapy, higher adherence among men than women could be explained by the fact that women are more prone to stress and to develop mental health conditions. Thus, emotional disorders like depression can be associated with non-adherence to drug therapy (10) .
Data on age is consistent with the literature; chronic patients' age affects adherence to drug therapy, as lower adherence was seen among younger patients (11) .
In regard to schooling, more educated patients were more adherent to therapy. Low schooling makes learning more difficult; as diabetes drug therapy gets more complex, patients are required to have more complex cognitive skills to be able to understand the prescribed drug therapy and to adhere to treatment for good glucose control.
As for family income, the study data corroborates the findings of another study that reported that those with family income less than five MMWs showed lower adherence when compared to those with higher income (9) .
As for factors related to the patient-provider relationship, the present study showed that patients' knowledge on diabetes and the proposed treatment directly influences their adherence to drug therapy.
Patients' perception of the expected treatment benefits increases their adherence. However, it was verified that health providers rarely assess patient knowledge as part of their clinical routine (7) .
Treatment adherence is a complex phenomenon influenced by multiple determinants. The patients' beliefs on drugs may be the key for their adherence to drug therapy, as they often choose to take a drug or not based on information they have about them.
A study reported that 82% of the diabetic patients studied believed the prescribed drugs would relieve their symptoms and 83% believed they would protect their health in the future. These subjects had higher adherence rates to drug therapy than those who distrusted it (98.5 and 87%, respectively) (4) .
It is crucial that patients are actively involved in drug therapy choice. When patients are involved at the moment health providers propose a therapeutic plan, they feel more motivated and their positive beliefs overcome their concerns about the drug prescribed, resulting in greater adherence to the proposed therapy (11) .
In regard to factors related to the therapeutic regimen, drug therapy adherence was more prevalent among those subjects who reported changes in their daily life as well in those who did not have side effects.
Depending on the type of drug prescribed, diabetic patients have to make changes in their daily life. The administration of certain drugs, such as insulin, requires patients to make adjustments in their daily habits, especially regarding meal times and physical activity.
As for drug side effects, they are quite often attributed to non-adherence to drug therapy.
However, patients are seldom asked about them during multiprofessional team care.
A study of type 2 diabetic patients reported that, for the majority (58%), side effects were a main factor limiting adherence. Only 23% of them reported these effects to their doctors and 83%
experienced them for more than a month (4) . Side effects can thus become chronic and patients may experience them for long periods of time, which can affect their adherence to drug therapy.
While prescribing drugs for diabetes management, prescribers should inform their patients on potential side effects that may occur in the beginning or throughout therapy. In every followup visit, providers should ask their patients about any side effects and how they are affecting drug use and make adjustments to the therapeutic regimen as needed. When providers show concern a b o u t p a t i e n t w e l l -b e i n g , p a t i e n t s a r e m o r e likely to attend the visits and have an adequate follow-up (5, 7) .
Patients should be asked about any problems affecting adherence due to the complexity of drug therapy. Doctors may offer patients less complex therapies, adjusted to the patient's needs, to help them better comply with the therapeutic regimen (7) .
In regard to disease-related factors, the literature shows a significant association between changes in HbA1 levels and patient adherence to drug therapy for diabetes management. For each 10% improvement in adherence to oral antidiabetic agents, HbA1 levels were reduced by about 0.19% (p<0.0001) (9) .
It is thus suggested that, in patients with abnormal HbA1 levels, rather than increasing the prescribed dose, adding a different drug or even replacing the prescribed drug, health providers should first assess patient adherence to drug therapy (12) .
More aggressive, earlier intervention in diabetes treatment has been recommended with a view to glucose management. This recommendation is supported by the fact that, in the United States, the proportion of type 2 diabetic patients with HbA1 levels below 7% has dropped 20% in recent years.
The Brazilian scenario is quite similar. It stresses patient non-adherence to the prescribed drug therapy (13) as a probable cause.
Another important aspect that affects disease-related adherence to drug therapy is diagnosis duration. The present study findings are consistent with those reported by the World Health Organization (WHO), pointing out a negative relationship between diabetes duration and patient adherence to drug therapy. Those patients with longer disease duration tend to be less adherent to treatment (14) .
Lower adherence rates to drug therapy for diabetes management is a matter of concern as disease progresses because diabetes is a progressive silent disease, and chronic complications due to poor glucose control are likely to increase with time.
As for patient knowledge on diabetes management, the study showed higher rates of adherence among those reporting poor glucose management. This is an important finding because it highlights the fact that patients with good metabolic control seem less concerned about disease management and have lower adherence rates. With respect to patient knowledge on diabetes drugs, adherence was higher among those subjects with limited knowledge.
Despite all recommendations and protocols, since patients are not properly advised on the use of oral antidiabetic agents, their use is inadequate, resulting in poor glucose control (13) . Limited knowledge on drug therapy has proven to have great impact on patients' health and quality of life, especially in those with one or more chronic conditions. Hospital admissions and premature Although different prevalence rates of adherence were found for all factors in the present study, these differences were not statistically significant. This could be explained by the small size of the convenience sample, which included patients attending a health service with the purpose of improving their knowledge on diabetes. It is thus a d i f f e r e n t i a t e d s a m p l e , b e c a u s e p a t i e n t s supposedly sought diabetes education to better understand their disease and drug therapy and, t h u s , i n c r e a s e a d h e r e n c e t o t h e p r e s c r i b e d therapy. In the light of the factors discussed here, efforts should be made to improve diabetic patient adherence to drug therapy and, consequently, diabetes management.
CONCLUSIONS
The present study found 78.3% patient adherence to antidiabetic drug therapy. Although different prevalences of adherence were seen for each factor studied, the association was not statistically significant. It can be concluded that, since the prevalence of adherence found in the present study is below that recommended in the literature, it is crucial that health providers assess adherence of patients to drug therapy in the event of poor glucose control and presumed failure of the prescribed therapeutic regimen.
